The European Medicines Agency’s management board has adopted a revamped procedure to deal with conflicts of interests during the assessment of drugs.
This is the last step in the tightening of the agency’s rules to make sure that its staff, scientific experts, committee or management board members have no financial or other interests that could affect their impartiality in the evaluation of medicines.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.